Why the study?
The authors sought to assess the incidence, risk factors, and long-term complications and survival associated with reoperation for bleeding following CABG in a nationwide cohort.
Does reoperation for bleeding following CABG affect long-term survival and MACCE in isolated CABG patients?
Does reoperation for bleeding following CABG affect long-term survival and MACCE in isolated CABG patients?
Reoperation for bleeding after CABG is associated with increased short-term mortality and complications, but 30-day survivors have long-term survival and MACCE rates comparable to non-reoperated patients.
Reoperation for bleeding signals higher short-term risks after CABG; leaves open independent effects on long-term MACCE and survival.
Objectives: We studied the incidence and risk factors of reoperation for bleeding following CABG in a nationwide cohort with focus on long-term complications and survival. Design: A retrospective study on 2060 consecutive, isolated CABG patients operated 2001–2016. Outcome of reoperated patients (n = 130) were compared to non-reoperated ones (n = 1930), including major adverse cardiac and cerebrovascular events (MACCE) and overall survival. Risk factors for reoperation were determined using multivariate logistic regression and a Cox proportional hazards model to assess prognostic factors of long-term survival. Median follow-up was 7.6 years. Results: One hundred thirty patients (6.3%) were reoperated with an annual decrease of 4.1% per year over the study period (p=.04). Major complications (18.5 vs. 9.6%) and 30-day mortality (8.5 vs. 1.9%,) were higher in the reoperation group (p<.001). The use of clopidogrel preoperatively (OR 3.62, 95% CI: 1.90–6.57) and reduced left ventricular ejection fraction (OR 2.23, 95% CI: 1.25–3.77) were the strongest predictors of reoperation, whereas off-pump surgery was associated with a lower reoperation risk (OR 0.44, 95% CI: 0.22–0.85). After exluding patients that died within 30 days postoperatively, no difference in long-term survival or freedom from MACCE was found between groups, and reoperation was not an independent risk factor for long-term mortality in multivariate analysis. Conclusions: The reoperation rate in this study was relatively high but decreased significantly over time. Reoperation was associated with twofold increased risk for major complications and fourfold 30-day mortality, but comparable long-term MACCE and survival rates. This implies that if patients survive the first 30 days following reoperation, their long-term outcome is comparable to non-reoperated patients.
No takes yet. Share an insight, caveat, or question.
Marteinsson et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: